Combined fertility treatment available

27 November 2007

Merck Serono has launched Pergoveris (follitropin alfa/lutropin alfa), indicated for the stimulation of follicular development in women with severe lutinising hormone (LH) and follicle stimulating hormone (FSH) deficiency.

Treatment with Pergoveris should be initiated under the supervision of a physician experienced in the treatment of fertility problems and given as a course of daily injections.


Treatment should be tailored to the individual patient’s response as assessed by measuring follicle size by ultrasound and oestrogen response. A recommended regimen commences with one vial of Pergoveris daily.

Further information: Merck Serono 020 8818 7200

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...